Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.
Publication
, Journal Article
Lewis, JP; Yerges-Armstrong, LM; Ellero-Simatos, S; Georgiades, A; Kaddurah-Daouk, R; Hankemeier, T
Published in: Clin Pharmacol Ther
November 2013
Interindividual variability in response to antiplatelet therapy results in higher platelet reactivity as well as higher rates of cardiovascular events. Despite substantial effort, the genetic and nongenetic determinants of antiplatelet variability remain poorly understood. Emerging pharmacometabolomic paradigms that integrate systems approaches such as pharmacogenomics have the potential to unveil novel biology regarding disease pathogenesis, reveal the effect of drugs on pathways, and allow better understanding of response variability. Such approaches offer great potential for personalized antiplatelet treatment.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
November 2013
Volume
94
Issue
5
Start / End Page
570 / 573
Location
United States
Related Subject Headings
- Platelet Aggregation Inhibitors
- Platelet Aggregation
- Pharmacology & Pharmacy
- Pharmacogenetics
- Metabolomics
- Humans
- Cardiovascular Diseases
- Aspirin
- 3214 Pharmacology and pharmaceutical sciences
- 1115 Pharmacology and Pharmaceutical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lewis, J. P., Yerges-Armstrong, L. M., Ellero-Simatos, S., Georgiades, A., Kaddurah-Daouk, R., & Hankemeier, T. (2013). Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. Clin Pharmacol Ther, 94(5), 570–573. https://doi.org/10.1038/clpt.2013.153
Lewis, J. P., L. M. Yerges-Armstrong, S. Ellero-Simatos, A. Georgiades, R. Kaddurah-Daouk, and T. Hankemeier. “Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.” Clin Pharmacol Ther 94, no. 5 (November 2013): 570–73. https://doi.org/10.1038/clpt.2013.153.
Lewis JP, Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Kaddurah-Daouk R, Hankemeier T. Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. Clin Pharmacol Ther. 2013 Nov;94(5):570–3.
Lewis, J. P., et al. “Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.” Clin Pharmacol Ther, vol. 94, no. 5, Nov. 2013, pp. 570–73. Pubmed, doi:10.1038/clpt.2013.153.
Lewis JP, Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Kaddurah-Daouk R, Hankemeier T. Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. Clin Pharmacol Ther. 2013 Nov;94(5):570–573.
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
November 2013
Volume
94
Issue
5
Start / End Page
570 / 573
Location
United States
Related Subject Headings
- Platelet Aggregation Inhibitors
- Platelet Aggregation
- Pharmacology & Pharmacy
- Pharmacogenetics
- Metabolomics
- Humans
- Cardiovascular Diseases
- Aspirin
- 3214 Pharmacology and pharmaceutical sciences
- 1115 Pharmacology and Pharmaceutical Sciences